BiogenHAM:IDP +4.05%73 Days Payable is 54.18 as of Mar. 2026, which is 29% below its 10-year median of 76.29. GuruFocus rates HAM:IDP with a GF Score™ of 73/100 and a GF Value™ of €166.45 (Modestly Overvalued). The stock has 7 warning signs investors should review. Among 920 Drug Manufacturers companies, Biogen ranks worse than 68.15% on this metric.
Biogen's average Accounts Payable for the
three
months ended in Mar. 2026 was €340 Mil. Biogen's Cost of Goods Sold for the
three
months ended in Mar. 2026 was €572 Mil.
Hence, Biogen's Days Payable for the
three
months ended in Mar. 2026 was 54.18.
The historical rank and industry rank for Biogen's Days Payable or its related term are showing as below:
HAM:IDP'
s Days Payable Range Over the Past 10 Years
Min: 60.04 Med: 76.29 Max: 99.65
Current: 60.04
During the past 13 years, Biogen's highest Days Payable was 99.65. The lowest was 60.04. And the median was 76.29.
HAM:IDP's Days Payable is ranked worse than 68.15% of 920
companies
in the Drug Manufacturers industry
Industry Median: 90.835
vs HAM:IDP: 60.04
Biogen's Days Payable
declined
from Mar. 2025 (60.14) to Mar. 2026 (54.18).
It may suggest that Biogenaccelerated paying its suppliers.
Biogen Days Payable Related Terms
Biogen Days Payable Historical Data
* Premium members only.
The historical data trend for Biogen's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HAM:IDP vs OGN, AMRN, SCLX: Days Payable Comparison
For the Drug Manufacturers - General subindustry, Biogen's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biogen Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Biogen's Days Payable distribution charts can be found below:
* The bar in red indicates where Biogen's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Biogen's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biogen (HAM:IDP) has a Days Payable of 54.18 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Biogen and its competitors. This is 29% below median its historical median of 76.29. Over the past decade, Biogen's Days Payable has ranged from 60.04 to 99.65. According to the industry distribution chart, Biogen ranks #627 out of 920 companies in the Drug Manufacturers industry, placing it in the top 68.2%.
Is Biogen's Days Payable too high?
Biogen's current Days Payable of 54.18 is 29% below median its 10-year median of 76.29. Over the past 10 years, this metric has ranged from a low of 60.04 to a high of 99.65. The Drug Manufacturers industry median Days Payable is 90.84. Biogen's value of 54.18 is 40.4% below this industry median. Based on the distribution chart, Biogen ranks #627 out of 920 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Biogen has a GF Score™ of 73/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Biogen's Days Payable compare to OGN and AMRN?
According to the Drug Manufacturers industry distribution chart, Biogen ranks #627 out of 920 companies for Days Payable. This places Biogen in the lower half of its industry. The industry median Days Payable is 90.84. Biogen's value of 54.18 is 40.4% below this benchmark. Historically, Biogen's own Days Payable has ranged from 60.04 to 99.65 over the past decade. While the company's 10-year median is 76.29 vs. the industry median of 90.84, Biogen has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.84, based on 920 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biogen's current Days Payable of 54.18 is 40.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Biogen and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biogen's current Days Payable is 54.18, which is 29% below median its own 10-year median of 76.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biogen stock overvalued right now?
Based on GuruFocus' analysis, Biogen (HAM:IDP) is currently considered Modestly Overvalued. The stock's GF Value™ is €166.45, compared to a current price of €187.44 — trading 12.6% above its estimated fair value. The current Days Payable is 54.18, which is 29% below median its 10-year median of 76.29 and 40.4% below the Drug Manufacturers industry median of 90.84. Biogen's overall GF Score™ is 73/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Biogen (HAM:IDP), the current Days Payable is 54.18 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biogen (HAM:IDP) Overvalued in 2026?
Based on GuruFocus' analysis, Biogen stock appears to be overvalued.
The current stock price of €187.44 is trading 12.6% above its estimated GF Value™ of €166.45.
GuruFocus considers Biogen to be Modestly Overvalued.
Key valuation signals for HAM:IDP:
Days Payable: 54.18 (29% below median its 10-year median of 76.29)
GF Value™: €166.45 vs. price of €187.44 (12.6% above fair value)
Industry Position: 40.4% below the Drug Manufacturers median (#627 of 920)
No single metric tells the full story. See the HAM:IDP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
73GF Score
Get the complete analysis for HAM:IDP
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:IDP has been successfully added to your 
